Burning Mouth Syndrome: Case Report

Mohan Gautam
Shivali Patel
Ibrahim M. Sablaban
Mauran Sivananthan

Follow this and additional works at: https://scholarlycommons.henryford.com/behavioralhealth_articles
The patient received only supportive care during his admission. Interestingly, halving of ferritin levels was observed in 1 day after cessation of lamotrigine, which corresponds to the half-life of ferritin,5 clearly supporting HLH as serious adverse event of lamotrigine. Venlafaxine was restarted on the second day after admission. Six days after admission, the patient had made a full clinical recovery, and his biochemical parameters had largely normalized and continued to do so during the next few weeks of outpatient follow-up.

Hemophagocytic lymphohistiocytosis has sporadically been described after initiation of lamotrigine. With an increasing number of reports surfacing in recent years, the association with this nontrivial condition is becoming more clear.6 Interestingly, reports are currently available in the literature. Such scarcity provides little guidance to the clinician confronted with this adverse event when it comes to treatment decisions. For example, our report indicates that early cessation of the drug enables patients to make a full recovery without treatment and that disease markers fall very quickly upon cessation of lamotrigine. Such observations may help forestall aggressive treatment of the HLH where this is not strictly necessary.

Antiepileptic drugs are known to modulate immune system activity and alter the production of cytokines. Through these mechanisms, immunogenic adverse effects have been well documented for this class of drugs, although newer agents have been less extensively described.12 Therefore, reports like this one should prompt clinicians to close monitoring of the patient in the weeks after the first prescription of lamotrigine or other antiepileptic drugs.

ACKNOWLEDGMENTS
The authors thank André van Rossum for providing imaging of the bone marrow aspirate.

AUTHOR DISCLOSURE INFORMATION
The authors declare no conflicts of interest.

Received November 10, 2020; accepted after revision February 8, 2021.

Marvyn T. Koning, MD
Department of Internal Medicine
Groene Hart Hospital
Gouda, the Netherlands
m.t.koning@lumc.nl

Cynthia J. Janmaat, MD
Henny G. Petelburg, MD, PhD
Nicolette L. Tiren-Verbeet, MD, PhD
Department of Internal Medicine
Groene Hart Hospital
Gouda, the Netherlands

REFERENCES

Burning Mouth Syndrome
Case Report

To the Editor:
Burning mouth syndrome (BMS), also known as glossodynia or stomatodynia, is characterized by burning oral pain in the absence of an identifiable lesion.1 The prevalence of BMS is estimated to be between 0.7% and 4.5%.2–4 This condition is more common in postmenopausal women3 and often co-occurs with other symptoms, such as parageusia and xerostomia.3

There are no laboratory tests to establish a definitive diagnosis of BMS.6 As BMS is associated with somatization, anxiety, depression, dissociation, and personality disorders,7 8 a patient's description of these symptoms may be overlooked. Herein, we present the case of a patient with bipolar disorder who developed BMS after the initiation ofquetiapine.

CASE PRESENTATION
The patient is a 65-year-old White woman with a longstanding history of bipolar 1 disorder with mixed features. The patient's symptoms were relatively controlled with 10-mg aripiprazole and 0.25-mg clonazepam daily. In May 2020, she reported increasing jaw tightness, and therefore, aripiprazole was cross-titrated with quetiapine. Concurrently, clonazepam was discontinued. By June 2020, the cross-titration was completed, and she was no longer taking aripiprazole, which was replaced with 300-mg quetiapine nightly. She reported resolution of her facial extrapyramidal symptoms and denied any adverse effects from quetiapine.

FIGURE 1. Histiocyte showing phagocytosis of numerous erythrocytes. Color image is available online only at www.psychopharmacology.com.
Throughout July 2020, she began to experience worsening xerostomia. She used sugarless gum and lemon drops/mints, but these did not alleviate symptoms. At this time, she demonstrated a weakly positive antinuclear antibody titer of 1:320. By August 2020, her symptoms had significantly intensified; she reported a constant burning sensation on her hard palate accompanied by a sore throat. The symptoms were severe enough to cause her distress during the day and interfere with sleep.

Subsequently, the patient underwent an extensive medical workup. Electrolytes were within normal limits, as were renal and liver functions. Anti–Sjögren syndrome A/anti–Sjögren syndrome B, anti–double-stranded DNA, C3 and C4 complement, and extractable nuclear antigen/anti-Smith/antibipolar cation antibodies were all negative. Complete blood count with differential, iron level, and hemoglobin/hematocrit level were within normal limits. Biopsy of her lip showed squamous mucosa, and biopsy of minor salivary gland showed focal fibrosis, focal atrophy, and minimal chronic inflammation. The focus score of 0 for focal fibrosis, focal atrophy, and minimal chronic inflammation was not consistent with Sjögren syndrome.9,10

Considering her negative medical workup, we suspected that she developed BMS secondary to quetiapine in October 2020. Quetiapine was cross-titrated with olanzapine over 4 weeks. Subsequently, while taking clonazepam and aripiprazole, both of which were prescribed previously,19 treatment options for BMS are limited and are largely based on cessation of the presumed offending agents. Further literature on psychopathological explanations for BMS, along with randomized controlled trials for potential therapeutics, would be welcomed contributions.

AUTHOR DISCLOSURE

The authors declare no conflicts of interest.

Patient’s verbal consent was obtained to develop and to publish this case report. Information has been deidentified to protect anonymity.

Received January 8, 2021; accepted after revision March 25, 2021.

Mohan Gautam, DO, MS
Department of Psychiatry
Henry Ford Health System
Detroit, MI
mgautam1@hfhs.org

Shivali Patel, MD
Ibrahim Sablaban, DO
Manthan Sivananthan, DO
Department of Psychiatry
Henry Ford Health System
Detroit, MI

REFERENCES